Skip to main content
. 2016 Jul 18;11(7):e0159034. doi: 10.1371/journal.pone.0159034

Fig 5. Effect of arenobufagin (Arg) on Na, K-ATPase activity, intracellular Ca(2+) level and ROS level.

Fig 5

(A) Quantitation of Na, K-ATPase activity in HeLa cells treated with arenobufagin(Arg) at different doses for 24h. (B) Western blotting results of Na, K-ATPase α1 and α3 in HeLa cells treated with arenobufagin(Arg) at different doses for 24 h. (C) Quantitation of the intracellular Ca(2+) level in HeLa cells treated with 10 nM arenobufagin for different time periods. (D) Quantitation of the intracellular ROS level in HeLa cells treated with 10 nM arenobufagin for different time periods. (E) Quantitation of the intracellular ROS level in HeLa cells treated with arenobufagin at different doses for 3h. (F) The viability of HeLa cells treated with 10 nM arenobufagin for 72 h in the presence of ROS scavenger NAC (N-acetyl cysteine). Data were statistical results of three independent experiments. Data were expressed as mean ± SD. *Significant difference from the control group at P<0.05.